Short answer
ANAPTYSBIO, INC (ANAB) filed an 8-K current report with the SEC on April 24, 2026 reporting Item EX-99.1 (Exhibit EX-99.1). Spin-off completed April 20, 2026, separating First Tracks Biotherapeutics and refocusing AnaptysBio on continuing operations.
ANAPTYSBIO, INC 8-K event analysis
AI summary of each reported item and its exhibits
Item EX-99.1 · Exhibit EX-99.1
- Spin-off completed April 20, 2026, separating First Tracks Biotherapeutics and refocusing AnaptysBio on continuing operations
- $100.0M initial cash distribution to First Tracks reduced AnaptysBio pro forma cash to $138.2M
- Continuing operations generated 2025 revenue $234.6M and pro forma net income $114.9M
- Pro forma 2025 accumulated deficit reached $926.0M, with stockholders’ equity negative $116.3M
- Additional spin-off costs include approximately $7.0M plus $2.0M of transition-services expenses
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ANAPTYSBIO, INC 8-K filings
Get the next ANAB 8-K as it lands
Follow ANAB for push alerts, or ask the research agent what this filing means.